LOGIN  |  REGISTER
Assertio

Streamline Health® Solutions Announces New eValuator™ Contract With Florida-Based Academic Medical Center

October 30, 2023 | Last Trade: US$2.31 0.26 -10.11
  • 1,000-bed Florida-based healthcare provider selected eValuator’s pre-bill code audit technology to improve coding accuracy

Atlanta, GA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has signed a new contract for the use of eValuator with a 1,000-bed, Epic-based academic medical center serving central Florida.

eValuator’s pre-bill code audit technology makes it easy for providers to identify, quantify and expedite correction of coding issues with the highest impact on revenue integrity. With eValuator, providers can optimize financial performance from their inpatient, outpatient, and professional-fee encounters through one platform without billing delays.

“We are pleased that our pre-bill revenue integrity solutions continue to gain market traction with large health systems,” stated Ben Stilwill, Chief Executive Officer. “Our team is excited to improve the revenue cycle of these institutions to ensure they are accurately paid for the care they’ve provided.”

About Streamline Health

Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net

To Learn More

Jacob Goldberger
Director, Investor Relations and FP&A
303.887.9625
This email address is being protected from spambots. You need JavaScript enabled to view it.

Assertio

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page